慢性乙型肝炎的免疫治疗研究进展  

Immuno-therapy for chronic hepatitis B

作　　者：乔艳(综述)[1] 徐东平(审校)[2] 李进(审校)[3] 

机构地区：[1]桂林医学院临床医学院,广西壮族自治区桂林市541004 [2]解放军302医院临床研究管理中心 [3]解放军302医院院务部

出　　处：《实用肝脏病杂志》2016年第4期493-496,共4页Journal of Practical Hepatology

基　　金：国家自然科学基金资助项目(编号81373136)

摘　　要：临床上应用的抗乙型肝炎病毒(HBV)药物主要有干扰素和核苷(酸)类似物两类,在大多数慢性HBV感染者即使经过长期的抗病毒治疗仍不能彻底清除病毒。感染的控制和病毒的清除有赖于机体的免疫系统。感染慢性化与机体特异性免疫功能,尤其是细胞免疫功能低下密切相关。通过增强抗HBV感染的免疫治疗是被人们寄予厚望的一种治疗策略。目前研究的热点主要包括免疫激动剂、特异性细胞毒性T淋巴细胞(CTL)负调节分子阻断剂、特异性CTL调节分子激动剂或佐剂、治疗性疫苗、特异性T细胞受体(TCR)转基因技术、携带嵌合抗原受体的T细胞和多糖类物质等,本文对近年来这方面的研究进展进行了综述。There are two categories of antiviral agents that have been commonly used in treatment of patients with chronic hepatitis B,e.g. interferons and nucleos （t）ide analogues. Most patients fail to obtain eradication of HBV even receiving a long-term treatment. Disease control and viral clearance depend on the host＇s immune responses,which is closely associated with specific-immunity,especially cellular immunity. Strategies of immunotherapies to boost or restore the virus-specific immune response of patients with chronic hepatitis B virus infection have been proposed for curing persistent infections. Currently, researches on immunotherapies focused on Toll-like receptors （TLR） agonists,negative immunomodulatory molecules of cytotoxic T lymphocyte （CTL）,CTL agonists,therapeutic vaccinations,specific T cell receptor （TCR） transgenic technology,chimeric antigen receptor T （CAR-T）cells,small molecule,etc. This review summarizes the recent progress in the above researches.

关 键 词：慢性乙型肝炎 免疫治疗 进展 

分 类 号：R730.51[医药卫生—肿瘤]